- Home
- XGN vs JLS Comparison
XGN vs JLS Comparison
Compare XGN & JLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XGN | JLS |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.7M | 94.1M |
| IPO Year | 2014 | 2009 |
Fundamental Metrics
Financial Performance| Metric | XGN | JLS |
|---|---|---|
| Price | $8.46 | $16.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $10.14 | N/A |
| AVG Volume (30 Days) | ★ 273.4K | 26.3K |
| Earning Date | 11-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.33% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.02 | N/A |
| Revenue Next Year | $10.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.59 | $16.01 |
| 52 Week High | $12.23 | $18.98 |
Technical Indicators
Market Signals| Indicator | XGN | JLS |
|---|---|---|
| Relative Strength Index (RSI) | 58.90 | 51.03 |
| Support Level | $7.81 | $16.01 |
| Resistance Level | $8.89 | $16.59 |
| Average True Range (ATR) | 0.42 | 0.24 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 58.33 | 81.07 |
Price Performance
Historical ComparisonAbout XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
About JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. The Fund's investment objective is to provide a high level of current income.